Primary information |
---|
ID | antitb_1256, |
Name | 23716047 |
N-Terminal modification | Eosinophil Cationic Protein (RNase 3) |
C-Terminal Modification | RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWRCKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNN |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | Disulphide linkage |
Chirality | Cyclic |
Nature | 70 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Secreted by eosinophil secondary granules |
Inhibition Concentration | Mycobacterium vaccae |
In Vitro/ In vivo | Mycobacterium vaccae strain (ATCC 15483) |
Cell Line | MIC = 20.0 ± 1.0 μM |
Inhibition Concentration | In vitro |
Sequence | 2013 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Membrane depolarization and permeabilization |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial and Antiparasitic |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1257, |
Name | 23716047 |
N-Terminal modification | Eosinophil Cationic Protein (RNase 3) |
C-Terminal Modification | RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWRCKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNN |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | Disulphide linkage |
Chirality | Cyclic |
Nature | 70 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Secreted by eosinophil secondary granules |
Inhibition Concentration | Mycobacterium vaccae |
In Vitro/ In vivo | Mycobacterium vaccae strain (ATCC 15483) |
Cell Line | IC50 = 11.6 ± 0.2 μM |
Inhibition Concentration | In vitro |
Sequence | 2013 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | None |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Membrane depolarization and permeabilization |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial and Antiparasitic |
Tertiary Structure (Technique) | Not Predicted), |